Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Intervalo de año de publicación
1.
Trop Anim Health Prod ; 47(6): 1061-6, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25894823

RESUMEN

The objective of this study was to determine if high milk-yielding Holstein cows testing positive for bovine tuberculosis (bTB) are affected in their reproductive performance and milk yield. For this purpose, 1044 healthy cows and 105 bTB reactor cows were used. Tuberculosis reactor cows were from four large commercial dairy operations from the same region which were transferred from their barns to an isolated dairy facility. Cows free from this disease were placed in the same barn as the bTB reactor cows but in an isolated division and served as control animals. The analysis of variance with a general linear model for binary data showed that the reproductive performance of bTB reactors was impaired; overall pregnancy per artificial insemination differed (P < 0.05) between bTB reactor and non-reactor cows (16.9 vs. 20.7%). Cows that were TB reactors required 4.7 ± 2.9 services per pregnancy compared with 4.3 ± 2.8 for control cows (P > 0.05). The intervals between calving and conception were similar between bTB reactors (154 ± 78 days) and control animals (150 ± 80 days). Control cows tended (P = 0.08) to produce more milk than bTB reactors over a 305-day lactation (10,684 ± 1720 vs. 10,345 ± 1736; mean ± SD). Serum metabolites indicative of nutritional stress did not differ between bTB reactor and non-reactor cows. It was concluded that both reproductive performance and milk yield decreased marginally in bTB reactor cows, which explains the reluctance of milk producers to get rid of these animals.


Asunto(s)
Industria Lechera , Lactancia , Leche/metabolismo , Tuberculosis Bovina/fisiopatología , Animales , Bovinos , Femenino , México , Embarazo , Estudios Prospectivos , Reproducción , Tuberculosis Bovina/sangre , Tuberculosis Bovina/complicaciones
2.
Cytometry B Clin Cytom ; 72(1): 34-42, 2007 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-17051524

RESUMEN

BACKGROUND: Glycosylphosphatidylinositol-anchored proteins (GPI-AP) are a heterogeneous group of proteins deficiently expressed in patients with paroxysmal nocturnal hemoglobinuria. Up till now, no study has been reported in which the exact patterns of expression of a large number of GPI-AP are quantitatively evaluated in normal bone marrow (BM) cells classified according to their lineage and maturation stage. METHODS: In the present study, we have quantitatively analyzed the expression of eleven different GPI-AP (CD14, CD16, CD24, CD48, CD52, CD58, CD59, CD66b, CD87, CD109 and CD157) during maturation of the neutrophil, monocytic, erythroid, lymphoid, basophil and plasmacytoid dendritic cells (DC) lineages in normal BM as a frame of reference for the understanding of the abnormal patterns of expression of GPI-AP observed in the BM of PNH patients. RESULTS: Our results show that expression of most GPI-AP varies during normal BM maturation, different profiles being frequently observed depending on the cell lineage or the GPI-AP analyzed. CONCLUSION: Overall, these results provide a detailed map GPI-AP expression during normal hematopoietic differentiation, which could serve as a basis for the identification and characterization of changes occurring in PNH.


Asunto(s)
Células de la Médula Ósea/citología , Diferenciación Celular , Glicosilfosfatidilinositoles/análisis , Hematopoyesis/fisiología , Adulto , Anciano , Antígenos CD/inmunología , Linfocitos B/citología , Basófilos/citología , Compartimento Celular , Linaje de la Célula , Células Dendríticas/citología , Células Eritroides/citología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Monocitos/citología , Neutrófilos/citología
3.
Leuk Res ; 30(1): 9-16, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16005514

RESUMEN

Recent studies concerning the pathophysiology of myelodysplastic syndromes (MDS) have shown evidences for the existence of complex interactions between hematopoietic stem cells and the bone marrow (BM) microenvironment. We analyzed the B-lymphocyte maturation in BM of patients with MDS. For this purpose, 41 newly-diagnosed patients were analyzed. Enumeration and characterization of CD34+ and CD34- B-cell precursors and mature B-lymphocytes was performed using multiparameter flow cytometry. BM from eight transplant donors and six orthopedic surgery patients were used as controls. CD34+/CD45(lo) B-cells were found in 17/22 patients with RA/RARS and in 5/13 with RAEB. In patients with RAEB-t and CMML no CD34+ B-cell precursors could be detected. A positive correlation was found between CD34+ and CD34- B-cell precursors (r=0.52). CD34+ B-cell precursors presented an inverse correlation with BM percentage of blasts and peripheral leukocytes and a positive one with hemoglobin. Asynchronous antigen expression (CD19+/CD79a- cells) was found in 7/11 cases of RA/RARS and 6/18 cases of RAEB in which this phenotype was examined. Abnormal patterns of expression for at least one antigen was found in 91% of RA/RARS cases and in 74% of RAEB. Underexpression of TdT and CD79a were the most frequent abnormalities. Our results present evidences of an abnormal B-cell maturation in MDS. This may be an evidence that B-lymphocytes are derived of the abnormal clone. But it may also be the consequence of influences of abnormalities of BM microenvironment leading to an impaired commitment and maturation of the B-cell line in MDS. Studies performed with purified well-characterized B-cells may further elucidate these abnormalities.


Asunto(s)
Antígenos CD/biosíntesis , Linfocitos B/metabolismo , Células de la Médula Ósea/metabolismo , Diferenciación Celular , Regulación Leucémica de la Expresión Génica , Síndromes Mielodisplásicos/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Linfocitos B/patología , Células de la Médula Ósea/patología , ADN Nucleotidilexotransferasa/metabolismo , Citometría de Flujo , Humanos , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/patología , Síndromes Mielodisplásicos/terapia
4.
Cytometry B Clin Cytom ; 70(1): 1-9, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16278833

RESUMEN

BACKGROUND: Multiparametric flow cytometry has become an indispensable but complex tool for the diagnosis of acute leukemias. Interpretation of immunophenotypic data within a six-parameter analytical space relies on the standardization and validation of the instrument, the reagents, and the procedure. To address whether or not residual normal lymphocytes, usually present within leukemic samples, can serve as internal quality control for fluorescence intensity, 116 leukemic and 35 normal samples were analyzed. METHODS: Eight laboratories participated in the study and recruited a total of 151 individuals including 29 patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 77 with acute myeloid leukemia (AML), 10 with T-cell precursor acute lymphoblastic leukemia (T-ALL), and 35 normal bone marrow donors. Lymphocytes were gated according to the CD45hi/SSClo gating strategy, after which median fluorescence intensities (MFI) as well as percentages of positive cells (%positive) for CD19, CD22, CD7, and CD3 were recorded. Nonparametric statistics were used to compare variation within and between laboratories. RESULTS: Normal lymphocytes within leukemic samples do not show substantial differences compared to lymphocytes from normal controls with respect to expression of CD19, CD22, CD7, and CD3. In particular, longitudinal control charts of MFI values for CD3 antigen provide useful information on analytical and instrument performance. CONCLUSION: Residual normal lymphocytes can serve as internal quality control for studies addressing fluorescence intensity in the setting of immunophenotyping of acute leukemias.


Asunto(s)
Citometría de Flujo/métodos , Inmunofenotipificación/métodos , Leucemia , Linfocitos/citología , Linfocitos/metabolismo , Enfermedad Aguda , Estudios de Casos y Controles , Fluorescencia , Humanos , Leucemia/diagnóstico , Control de Calidad , Estándares de Referencia
5.
Haematologica ; 90(1): 54-9, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15642669

RESUMEN

BACKGROUND AND OBJECTIVES: Elderly patients with acute myeloid leukemia (AML) have a less favorable outcome, which has been related, among other factors, to multidrug resistance (MDR) phenotypes. DESIGN AND METHODS: Freshly obtained erythrocyte-lysed bone marrow samples from 150 elderly patients (> 65 years) with de novo AML and 30 younger AML patients were analyzed using a 4-color immunofluorescence technique for quantitative expression of proteins associated with apoptosis (bcl-2, bax, APO2.7) and MDR (P-gp, MRP, LRP) in 3 blast cell subpopulations, defined according to their maturation stage. RESULTS: Although a homogeneous CD34+ blast cell population was more frequent in the elderly patients, (25% vs 7%, p=0.02), no statistically significant differences were detected between the two age groups in the expression of either apoptosis- or MDR-associated proteins, except for slightly higher quantities of LRP protein in the more immature CD34+ blast cell subset in the elderly AML cases (p=0.04). Interestingly, when different blast cell populations were compared, immature (CD34+) blast cells were characterized by higher levels of bcl-2 in both age groups and lower levels of APO2.7 in the elderly group. In addition, higher P-gp levels were found in CD34+ blast cells than in CD34-- ones in elderly AML patients. Reactivity for LRP was low in both elderly and younger patients. INTERPRETATION AND CONCLUSIONS: In summary, our results suggest that the higher resistance to chemotherapy observed in elderly AML patients could be related to a higher incidence of cases with a CD34+ homogeneous blast cell population, since these blast cells frequently display a more pronounced anti-apoptotic and MDR1 phenotype.


Asunto(s)
Apoptosis/efectos de los fármacos , Crisis Blástica/patología , Leucemia Mieloide/tratamiento farmacológico , Leucemia Mieloide/patología , Enfermedad Aguda , Adulto , Factores de Edad , Anciano , Antígenos CD34 , Resistencia a Múltiples Medicamentos , Femenino , Genes MDR/genética , Genes MDR/fisiología , Humanos , Inmunofenotipificación , Cariotipificación , Leucemia Mieloide/genética , Leucemia Mieloide/inmunología , Masculino , Persona de Mediana Edad
6.
Clin Cancer Res ; 10(22): 7599-606, 2004 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-15569991

RESUMEN

Myelodysplastic syndromes and acute myeloid leukemia (AML) are heterogeneous disorders in which conflicting results in apoptosis and multidrug resistance (MDR) have been reported. We have evaluated by multiparameter flow cytometry the expression of apoptosis- (APO2.7, bcl-2, and bax) and MDR-related proteins [P-glycoprotein (P-gp), multidrug resistance protein (MRP), and lung resistance protein (LRP)] specifically on bone marrow (BM) CD34+ cells, and their major CD32-/dim and CD32+ subsets, in de novo AML (n=90), high-risk myelodysplastic syndrome (n=9), and low-risk myelodysplastic syndrome (n=21) patients at diagnosis, and compared with normal BM CD34+ cells (n=6). CD34+ myeloid cells from AML and high-risk myelodysplastic syndrome patients displayed higher expression of bcl-2 (P <0.0001) and lower reactivity for APO2.7 (P=0.002) compared with low-risk myelodysplastic syndrome and normal controls. Similar results applied to the two predefined CD34+ myeloid cell subsets. No significant differences were found in the expression of P-gp, MRP, and LRP between low-risk myelodysplastic syndrome patients and normal BM, but decreased expression of MRP (P <0.03) in AML and high-risk myelodysplastic syndromes and P-gp (P=0.008) in high-risk myelodysplastic syndromes were detected. Hierarchical clustering analysis showed that low-risk myelodysplastic syndrome patients were clustered next to normal BM samples, whereas high-risk myelodysplastic syndromes were clustered together and mixed with the de novo AML patients. In summary, increased resistance to chemotherapy of CD34+ cells from both AML and high-risk myelodysplastic syndromes would be explained more appropriately in terms of an increased antiapoptotic phenotype rather than a MDR phenotype. In low-risk myelodysplastic syndromes abnormally high apoptotic rates would be restricted to the CD34- cell compartments.


Asunto(s)
Antígenos CD34/biosíntesis , Células de la Médula Ósea/metabolismo , Leucemia Mieloide Aguda/metabolismo , Síndromes Mielodisplásicos/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Apoptosis , Análisis por Conglomerados , Resistencia a Antineoplásicos , Citometría de Flujo , Humanos , Inmunofenotipificación , Proteínas de Neoplasias/biosíntesis , Fenotipo , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Riesgo , Partículas Ribonucleoproteicas en Bóveda/biosíntesis , Proteína X Asociada a bcl-2
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA